MORGAN STANLEY PLC/CALL/INCYTE CO./70/0.5/20.09.24 | Market Closed - Börse Stuttgart 11:43:40 17/05/2024 pm IST | ||
| 0.33 EUR | -10.81% |
|
| Current month | +32.00% | ||
| 1 month | -10.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.33 | -10.81% |
| 16/24/16 | 0.37 | +8.82% |
| 15/24/15 | 0.34 | -15.00% |
| 14/24/14 | 0.4 | -13.04% |
| 13/24/13 | 0.46 | +70.37% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 11:43 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9GR8 |
| ISIN | DE000ME9GR89 |
| Date issued | 01/03/2024 |
| Strike | 70 $ |
| Maturity | 20/09/2024 (126 Days) |
| Parity | 2 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.96 € |
|---|---|
| Lowest since issue | 0.239 € |
| Spread | 0.13 € |
| Spread % | 28.26% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.1
USD
Average target price
73.35
USD
Spread / Average Target
+28.46%
- Stock Market
- Warrants
- Warrant
